Zomedica Corp Net Income per Employee (ZOMDF), current and historic results, rankings and more, Quarterly Fundamentals - CSIMarket
CSIMarket
 


Zomedica Corp   (NONE: ZOMDF)
 

Zomedica Net Income per Employee

ZOMDF's Quarterly Results, Trends, Rankings, Statistics
Zomedica Corp recorded a cumulative net loss of $-23 million during 12 month ending in the first quarter 2026.
The Healthcare sector has seen employees of 102 other companies achieving higher income per employee. While income per employee total ranking has improved so far to 3122, from total ranking in previous quarter at 4067.


What is Income per Employee Ratio?






ZOMDF Net Income per Employee (Mar 31 2026)
I. Quarter
(Dec 31 2025)
IV. Quarter
(Sep 30 2025)
III. Quarter
(Jun 30 2025)
II. Quarter
(Mar 31 2025)
I. Quarter
Y / Y Net Income Change - - - - -
Net Income per Employee (TTM) $ -160,163 -580,553 -599,447 -603,532 -720,787
ZOMDF's Total Ranking # 3122 # 4067 # 3717 # 3811 # 3901
Seq. Net Income Change - - - - -


ZOMDF Net Income per Employee Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 103
Healthcare Sector # 348
Overall Market # 3122

Net Income per Employee Statistics
High Average Low
$ 179,778 $ -124,312 $ -720,787
(Sep 30 2019)   (Mar 31 2025)







Companies with similar Income per Employee for 12 month ending Mar 31 2026, within Healthcare Sector Income per Employee Income 12 month ending Mar 31 2026Number of Employees Mar 31 2026


Date modified: 2026-08-30T14:57:43+00:00




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.